Indaptus Therapeutics Q3 Net Loss Narrows 65% to $1.05 Million

• Indaptus Therapeutics’ third-quarter 2026 net loss narrowed 65% year over year to $1.05 million.
• Quarterly research and development expenses fell 82% to $271,204, primarily due to lower Decoy20 clinical costs and reduced payroll expenses.
• Cash, cash equivalents and short-term investments totaled approximately $30.6 million at September 30, 2026.
• A roughly $24 million private placement closed October 16, with approximately $3.5 million in remaining proceeds received in October.
• Planned research includes early-stage and preclinical evaluation of a potential neurotechnology- and neural-network-based device for certain sleep-related conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611131605PRIMZONEFULLFEED9877283) on November 13, 2026, and is solely responsible for the information contained therein.